200 related articles for article (PubMed ID: 34513316)
21. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.
Liu LT; Liang YJ; Guo SS; Xie Y; Jia GD; Wen DX; Tang LQ; Chen QY; Mai HQ
Head Neck; 2022 Jan; 44(1):34-45. PubMed ID: 34636116
[TBL] [Abstract][Full Text] [Related]
22. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
23. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana.
Ayee R; Ofori MEO; Tagoe EA; Languon S; Searyoh K; Armooh L; Bilson-Amoah E; Baidoo K; Kitcher E; Wright E; Quaye O
Viruses; 2020 Jul; 12(7):. PubMed ID: 32708700
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
25. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
26. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
Lee AZE; Tan LSY; Lim CM
Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus infection and nasopharyngeal carcinoma.
Tsao SW; Tsang CM; Lo KW
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
[TBL] [Abstract][Full Text] [Related]
29. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.
Muraro E; Vaccher E; Furlan C; Fratta E; Fanetti G; Fae' DA; Martorelli D; Cangemi M; Polesel J; Navarria F; Gobitti C; Comaro E; Scaini C; Pratesi C; Zanussi S; Lupato V; Grando G; Giacomarra V; Sulfaro S; Barzan L; Dolcetti R; Steffan A; Canzonieri V; Franchin G
Pathol Oncol Res; 2020 Oct; 26(4):2459-2467. PubMed ID: 32564263
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
[TBL] [Abstract][Full Text] [Related]
32. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
33. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
[TBL] [Abstract][Full Text] [Related]
36. Relationship between PPP1R15A gene polymorphism (rs611251) and Epstein-Barr virus-associated tumors.
Song Y; Liu S; Zhao Z; Zhang Y; Yang Y; Luo B
Acta Virol; 2017; 61(4):445-452. PubMed ID: 29186961
[TBL] [Abstract][Full Text] [Related]
37. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
Huang CL; Sun ZQ; Guo R; Liu X; Mao YP; Peng H; Tian L; Lin AH; Li L; Shao JY; Sun Y; Ma J; Tang LL
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):355-361. PubMed ID: 30682489
[TBL] [Abstract][Full Text] [Related]
38. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
39. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
40. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]